Highlights of This Issue 6059

SPECIAL FEATURES

CCR Translations

6061  Harnessing Immune Responses in the Tumor Microenvironment: All Signals Needed
Dung T. Le and Elizabeth M. Jaffee
See related article, p. 6286

6064  Test-Firing Ammunition for Spliceosome Inhibition in Cancer
Scott M. Dehm
See related article, p. 6296

CCR Perspectives in Drug Approval

6067  Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Previously Received Docetaxel: U.S. Food and Drug Administration Drug Approval Summary

Molecular Pathways

6074  Molecular Pathways: Adipose Inflammation as a Mediator of Obesity-Associated Cancer
Louise R. Howe, Kotha Subbaramaiah, Clifford A. Hudis, and Andrew J. Dannenberg

6084  Molecular Pathways: Induction of Polyploidy as a Novel Differentiation Therapy for Leukemia
Diane S. Krause and John D. Crispino

Review

6089  Lessons Learned from Radiation Oncology Clinical Trials
Fei-Fei Liu, for the workshop participants, Paul Okunieff, G. J. Bernhard, Helen B. Stone, Stephen Yoo, C. Norman Coleman, Bhadrasain Vikram, Martin Brown, John Buatti, and Chandan Guha

HUMAN CANCER BIOLOGY

Semaphorin 4F as a Critical Regulator of Neuroepithelial Interactions and a Biomarker of Aggressive Prostate Cancer
Yi Ding, Dandan He, Diego Fiorentin, Anna Frolov, Sue Hilsenbeck, Michael Ittmann, Dov Kadmon, Brian Miles, David Rowley, and Gustavo Ayala

Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein

Hypoxic Activation of the PERK/eIF2α Arm of the Unfolded Protein Response Promotes Metastasis through Induction of LAMP3
Hilda Mujcic, Anika Nagelkerke, Kasper M.A. Rouschop, Stephen Chung, Naz Chaudary, Paul N. Span, Blaise Clarke, Michael Milosevic, Jenna Sykes, Richard P. Hill, Marnin Kortitinsky, and Bradly G. Wouters

CANCER THERAPY: PRECLINICAL

Adrenomedullin Blockade Suppresses Growth of Human Hormone–Independent Prostate Tumor Xenograft in Mice
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>6163</td>
<td>Glucocorticoid Receptor Antagonism as a Novel Therapy for Triple-Negative Breast Cancer</td>
<td>Maxwell N. Skor, Erin L. Wonder, Masha Kocherginsky, Anju Goyal, Ben A. Hall, Yi Cai, and Suzanne D. Conzen</td>
</tr>
<tr>
<td>6205</td>
<td>Combination Therapy with a Second-Generation Androgen Receptor Antagonist and a Metastasis Vaccine Improves Survival in a Spontaneous Prostate Cancer Model</td>
<td>Andressa Ardiani, Benedetto Farsaci, Conni J. Rogers, Andy Prottter, Zhimin Guo, Thomas H. King, David Apelian, and James W. Hodge</td>
</tr>
<tr>
<td>6219</td>
<td>Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models</td>
<td>Sara A. Flanigan, Todd M. Pitts, Timothy P. Newton, Gillian N. Kulikowski, Aik Choon Tan, Martine C. McManus, Anna Spreatico, Maria I. Kachaeva, Heather M. Selby, John J. Tentler, S. Gail Eckhardt, and Stephen Leong</td>
</tr>
<tr>
<td>6230</td>
<td>JAK1/2 and Pan-Decetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2V617F-Driven Disease</td>
<td>Emeline Evrot, Nicolas Ebel, Vincent Romanet, Claudia Roelli, Rita Andreu, Zhian Qian, Arno Dölemyer, Ernesta Damassama, Dario Sterker, Robert Cozens, Francesco Hofmann, Masato Murakami, Fabienne Buffert, and Thomas Radimerski</td>
</tr>
<tr>
<td>6242</td>
<td>Molecular Chaperone gp96 is a Novel Therapeutic Target of Multiple Myeloma</td>
<td>Yumpeing Hua, Shai White-Gilbertson, Joshua Kellner, Saleh Rachidi, Saad Z. Usmami, Gabriela Chiosis, Ronald DePinho, Zihai Li, and Bei Liu</td>
</tr>
<tr>
<td>6245</td>
<td>Associations between Single-Nucleotide Polymorphisms in the PI3K–PTEN–AKT–mTOR Pathway and Increased Risk of Brain Metastasis in Patients with Non–Small Cell Lung Cancer</td>
<td>Qianxia Li, Ju Yang, Qianqian Yu, Huanlei Wu, Bo Liu, Huilua Xiong, Guangyuan Hu, Jing Zhao, Xianglin Yuan, and Zhongxing Liao</td>
</tr>
<tr>
<td>6252</td>
<td>Validation of a Proliferation-Based Expression Signature as Prognostic Marker in Early Stage Lung Adenocarcinoma</td>
<td>Ignacio I. Wistuba, Carmen Behrens, Francesca Lombardi, Susanne Wagner, Junya Fujimoto, M. Gabriela Raso, Lorenzo Spaggiari, Domenico Galetta, Rohyn Riley, Elisha Hughes, Julia Reid, Zaina Sangale, Steven G. Swisher, Neda Kalhor, Cesar A. Moran, Alexander Gutin, Jerry S. Lanchbury, Massimo Barberis, and Edward S. Kim</td>
</tr>
</tbody>
</table>
Promoter Hypomethylation of EpCAM-Regulated Bone Morphogenetic Protein Gene Family in Recurrent Endometrial Cancer
Ya-Ting Hsu, Fei Gu, Yi-Wen Huang, Joseph Liu, Jianhuaxuan Ruan, Rui-Lan Huang, Chiou-Mii Wang, Chun-Liang Chen, Rohit R. Jadhav, Hung-Cheng Lai, David G. Mutch, Paul J. Goodfellow, Ian M. Thompson, Nameer B. Kirma, and Tins Hui-Ming Huang

Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia
Mauricio Burotto, Maryalice Stelter-Stevenson, Evgeny Arons, Hong Zhou, Wyndham Wilson, and Robert J. Kreitman

CANCER THERAPY: CLINICAL

A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
See related article, p. 6061

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer
Robert J. Cardnell, Ying Feng, Lixia Diao, You-Hong Fan, Fatemah Masrorpour, Jing Wang, Yuqiao Shen, Gordon B. Mills, John D. Minna, John V. Heymach, and Lauren A. Byers

Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors
Ferry A.L.M. Eskens, Francisco J. Ramos, Herman Burger, James P. O’Brien, Adelaidea Piera, Maja J.A. de Jonge, Yoshiharu Mizui, Erik A.C. Wiemer, Maria Josepa Carreras, Jose Baselga, and Josep Tabernero
See related article, p. 6064

Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Letter

Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study

LETTERS TO THE EDITOR

Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Response
Klaus G. Griewank, Henrike Westekemper, Bastian Schilling, Elisabeth Livingstone, Tobias Schimming, Antje Sucker, Uwe Hillen, Klaus-Peter Steuhl, Lisa Zimmer, and Dirk Schadendorf

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer
Robert J. Cardnell, Ying Feng, Lixia Diao, You-Hong Fan, Fatemah Masrorpour, Jing Wang, Yuqiao Shen, Gordon B. Mills, John D. Minna, John V. Heymach, and Lauren A. Byers

Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Letter

Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Response
Klaus G. Griewank, Henrike Westekemper, Bastian Schilling, Elisabeth Livingstone, Tobias Schimming, Antje Sucker, Uwe Hillen, Klaus-Peter Steuhl, Lisa Zimmer, and Dirk Schadendorf

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer
Robert J. Cardnell, Ying Feng, Lixia Diao, You-Hong Fan, Fatemah Masrorpour, Jing Wang, Yuqiao Shen, Gordon B. Mills, John D. Minna, John V. Heymach, and Lauren A. Byers
ABOUT THE COVER

Cellular internalization of siRNA (red fluorescence) delivered by the nanocarrier (green fluorescence) specifically targeted to cancer cells. Superimposition of red (siRNA) and green (nanocarrier) fluorescence images gives yellow color. For details, see the article by Shah and colleagues on page 6193 of this issue.